Document Detail


The efficacy and safety of terbinafine in children.
MedLine Citation:
PMID:  12956204     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In summary, terbinafine is a broad-spectrum allylamine, which has been used to treat superficial fungal infections including onychomycosis, and some systemic mycoses in adults. With a fungicidal activity, low minimum inhibitory concentration value, and high selectivity for fungal squalene epoxidase, terbinafine has demonstrated good efficacy in superficial fungal infections. Its lipophilic nature provides excellent, widespread absorption into hair, skin, and nails where it can eradicate fungal infection. Terbinafine has been shown to be effective and safe in several studies of the treatment of tinea capitis and onychomycosis in children. When treating Trichophyton tinea capitis the length of therapy may be 2 or 4 weeks. Microsporum tinea capitis may require somewhat higher or longer doses of terbinafine for adequate efficacy. These regimens still tend to be shorter than treatment with griseofulvin, and terbinafine may provide a higher compliance and a more cost-effective means of managing tinea capitis. It is possible that even higher cure rates and a shorter duration of therapy may be achieved following further optimization of treatment regimens that use a higher daily dosage of terbinafine than is currently recommended. The evidence is strongly in favor of using terbinafine to treat superficial fungal infections in children.
Authors:
Aditya K Gupta; Elizabeth A Cooper; Charles W Lynde
Related Documents :
12047684 - Diagnosis and management of paediatric hepatitis c virus infection.
8222904 - A brief introduction to a nation-wide sampling survey on schistosomiasis.
24913734 - Seeing it my way: living with childhood onset visual disability.
19460194 - Seroprevalence of toxocara canis infection among asymptomatic children with eosinophili...
23671384 - Recommendations for mobility in children with spinal cord injury.
20686924 - Health-related quality of life of iranian children with attention deficit/hyperactivity...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Dermatologic clinics     Volume:  21     ISSN:  0733-8635     ISO Abbreviation:  Dermatol Clin     Publication Date:  2003 Jul 
Date Detail:
Created Date:  2003-09-05     Completed Date:  2003-10-10     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8300886     Medline TA:  Dermatol Clin     Country:  United States    
Other Details:
Languages:  eng     Pagination:  511-20     Citation Subset:  IM    
Affiliation:
Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Science Center (Sunnybrook Site), University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada. agupta@execulink.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Antifungal Agents / administration & dosage,  adverse effects,  therapeutic use*
Child
Child Welfare
Drug Administration Schedule
Griseofulvin / administration & dosage,  adverse effects,  therapeutic use*
Humans
Naphthalenes / administration & dosage,  adverse effects,  therapeutic use*
Onychomycosis / drug therapy*,  microbiology,  pathology
Tinea Capitis / drug therapy*,  microbiology,  pathology
Chemical
Reg. No./Substance:
0/Antifungal Agents; 0/Naphthalenes; 126-07-8/Griseofulvin; 91161-71-6/terbinafine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How to improve cure rates for the management of onychomycosis.
Next Document:  Efficacy and safety of itraconazole use in children.